Bio-Path Holdings, Inc. (BPTH) Appoints Amy P. Sing, M.D. To Its Board Of Directors

Bio-Path Holdings, Inc. (BPTH) Appoints Amy P. Sing, M.D. To Its Board Of Directors

Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced the appointment of Amy P. Sing, M.D. to its Board of Directors, bringing the number of board members to five.

Dr. Sing, 56, currently serves as Senior Director of Medical Affairs at Genomic Health, Inc., a leading publicly held biotechnology company that assists physicians and patients in making personalized cancer treatment decisions. 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.